Sale

Retinal Vein Occlusion Market

Retinal Vein Occlusion Market Size, Share, Trends, Report: By Type: Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion; By Condition: Non-Ischemic, Ischemic; By Diagnosis: Optical Coherence Tomography (OCT), Fundoscopic Examination, Others; By Treatment Type; By End User; Regional Analysis; Supplier Landscape; 2024-2032

Retinal Vein Occlusion Market Outlook

The retinal vein occlusion market size was valued at USD 12.4 billion in 2023, driven by the rising incidence of geriatric population. The market is expected to grow at a CAGR of 13.03% during the forecast period of 2024-2032, with the values likely to rise from USD 14 billion in 2024 to USD 37.2 billion by 2032.

 

Retinal Vein Occlusion: Introduction

Retinal vein occlusion is a condition characterized by the blockage of small veins carrying blood away from the retina. It may induce sudden blurring or vision loss in one part or the entire eye. Retinal vein occlusion is caused by hardening of veins (atherosclerosis) and blood clot formation. The venous blockage can be broadly divided into two categories, namely, central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). Treatment includes anti-vascular endothelial growth factor injections or focal laser procedures among others. The treatment may vary from patient to patient.

 

Retinal Vein Occlusion Market Analysis

With the increasing prevalence of sedentary lifestyle and obesity, the incidence of atherosclerosis, also known as hardening of the arteries, has increased. Atherosclerosis is one of the major causes of retinal vein occlusion along with other risk factors like diabetes, high blood pressure, macular edema, and glaucoma. The growing occurrence of these factors has fueled the retinal vein occlusion market demand.

 

Retinal vein occlusion management has been a key area of attention amongst the researchers. With the rising number of drug approvals for disease management, the market value is anticipated to grow in the forecast period. In October 2023, FDA approved Genentech’s Vabysmo (faricimab-svoa) for the treatment of retinal vein occlusion, based on two phase III studies showcasing early and persistent vision improvements in patients with the condition.

 

The retinal vein occlusion market growth is driven by the advent of new diagnostic and management tools for facilitating better understanding of the pathophysiology of the disease. Multimodal imaging techniques such as optical coherence tomography (OCT), optical coherence tomography angiography, choroidal imaging and fundus fluorescein angiography are commonly used diagnostic methods.

 

Retinal Vein Occlusion Market Segmentation

Market Breakup by Type

  • Branch Retinal Artery Occlusion
  • Central Retinal Vein Occlusion

 

Market Breakup by Condition

  • Non-Ischemic
  • Ischemic

 

Market Breakup by Diagnosis

  • Optical Coherence Tomography (OCT)
  • Fundoscopic Examination
  • Fluorescein Angiography
  • Others

 

Market Breakup by Treatment Type

  • Antivascular Endothelial Growth Factor
  • Corticosteroid Drugs
  • Laser Retinal Photocoagulation
  • Others

 

Market Breakup by End User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings
  • Others

 

Market Breakup by Region 

  • United States
  • EU-4 and the United Kingdom 
    • Germany 
    • France 
    • Italy 
    • Spain 
    • United Kingdom
  • Japan

 

Retinal Vein Occlusion Market Overview

The retinal vein occlusion market share has been dominated by the United States in the historical period. The presence of key healthcare companies can be considered as a major factor fueling the market size. With a robust healthcare infrastructure, scientists can easily integrate numerous technical advancements into their research and develop effective treatment alternatives for the patients.

 

In Europe, the population is at a higher risk of retinal vein occlusion largely due to high geriatric population. Identifying the risk, the government has been proactive in providing the right awareness to the people. Moreover, the region has been witnessing mergers and acquisitions amongst MedTech companies to expand their product portfolio and cater to the market demand.

 

Retinal Vein Occlusion Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Allergan
  • Bayer AG
  • IRIDEX Corporation
  • Lumenis
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Merck & Co.
  • Carl Zeiss
  • AbbVie Inc.
  • CalciMedica Inc.
  • Outlook Therapeutics, Inc.
  • Kodiak Sciences Inc.
  • Aerie Pharmaceuticals Inc.

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Condition
  • Diagnosis
  • Treatment Type
  • End User
  • Region
Breakup by Type 
  • Branch Retinal Artery Occlusion
  • Central Retinal Vein Occlusion
Breakup by Condition
  • Non-Ischemic
  • Ischemic
Breakup by Diagnosis
  • Optical Coherence Tomography (OCT)
  • Fundoscopic Examination
  • Fluorescein Angiography
  • Others
Breakup by Treatment Type
  • Antivascular Endothelial Growth Factor
  • Corticosteroid Drugs
  • Laser Retinal Photocoagulation
  • Others
Breakup by End User
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings
  • Others
Breakup by Region
  • United States    
  • EU-4 and the United Kingdom
  • Japan
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Allergan
  • Bayer AG
  • IRIDEX Corporation
  • Lumenis
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals
  • Merck & Co.
  • Carl Zeiss
  • AbbVie Inc.
  • CalciMedica Inc.
  • Outlook Therapeutics, Inc.
  • Kodiak Sciences Inc.
  • Aerie Pharmaceuticals Inc.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Retinal Vein Occlusion Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Retinal Vein Occlusion Epidemiology Analysis – 7MM  
    5.1    7MM Epidemiology Scenario Overview (2017-2032)
    5.2    United States Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
    5.3    EU-4 and United Kingdom Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
        5.3.1    Germany Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
        5.3.2    France Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
        5.3.3    Italy Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
        5.3.4    Spain Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
        5.3.5    United Kingdom Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
    5.4    Japan Retinal Vein Occlusion Epidemiology Forecast (2017-2032)
6    Retinal Vein Occlusion Market Overview – 7MM
    6.1    Retinal Vein Occlusion Market Historical Value (2017-2023) 
    6.2    Retinal Vein Occlusion Market Forecast Value (2024-2032)
7    Retinal Vein Occlusion Market Landscape – 7MM
    7.1    Retinal Vein Occlusion Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Retinal Vein Occlusion Product Landscape
        7.2.1    Analysis by Products
        7.2.2    Analysis by Type
        7.2.3    Analysis by Route of Administration
8    Retinal Vein Occlusion Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Retinal Vein Occlusion Market Dynamics
    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Retinal Vein Occlusion Market Segmentation – 7MM
    11.1    Retinal Vein Occlusion Market by Type
        11.1.1    Market Overview
        11.1.2    Branch Retinal Artery Occlusion
        11.1.3    Central Retinal Vein Occlusion
    11.2    Retinal Vein Occlusion Market by Condition
        11.2.1    Market Overview
        11.2.2    Non-Ischemic
        11.2.3    Ischemic
    11.3    Retinal Vein Occlusion Market by Diagnosis
        11.3.1    Market Overview
        11.3.2    Optical Coherence Tomography (OCT)
        11.3.3    Fundoscopic Examination
        11.3.4    Fluorescein Angiography
        11.3.5    Others
    11.4    Retinal Vein Occlusion Market by Treatment Type
        11.4.1    Market Overview
        11.4.2    Antivascular Endothelial Growth Factor
        11.4.3    Corticosteroid Drugs
        11.4.4    Laser Retinal Photocoagulation
        11.4.5    Others
    11.5    Retinal Vein Occlusion Market by End User
        11.5.1    Market Overview
        11.5.2    Hospitals
        11.5.3    Clinics
        11.5.4    Ambulatory Surgical Centers
        11.5.5    Homecare Settings
        11.5.6    Others
    11.6    Retinal Vein Occlusion Market by Region
        11.6.1    Market Overview
        11.6.2    United States    
        11.6.3    EU-4 and the United Kingdom
            11.6.3.1    Germany
            11.6.3.2    France
            11.6.3.3    Italy
            11.6.3.4    Spain
            11.6.3.5    United Kingdom
        11.6.4    Japan
12    United States Retinal Vein Occlusion Market
    12.1    Retinal Vein Occlusion Market Historical Value (2017-2023) 
    12.2    Retinal Vein Occlusion Market Forecast Value (2024-2032)
    12.3    Retinal Vein Occlusion Market by Disease Type
    12.4    Retinal Vein Occlusion Market by Treatment Type
13    EU-4 and United Kingdom Retinal Vein Occlusion Market
    13.1    Retinal Vein Occlusion Market Historical Value (2017-2023) 
    13.2    Retinal Vein Occlusion Market Forecast Value (2024-2032)
    13.3    Germany Retinal Vein Occlusion Market Overview
        13.3.1    Retinal Vein Occlusion Market by Disease Type
        13.3.2    Retinal Vein Occlusion Market by Treatment Type
    13.4    France Retinal Vein Occlusion Market Overview
        13.4.1    Retinal Vein Occlusion Market by Disease Type
        13.4.2    Retinal Vein Occlusion Market by Treatment Type
    13.5    Italy Retinal Vein Occlusion Market Overview
        13.5.1    Retinal Vein Occlusion Market by Disease Type
        13.5.2    Retinal Vein Occlusion Market by Treatment Type
    13.6    Spain Retinal Vein Occlusion Market Overview
        13.6.1    Retinal Vein Occlusion Market by Disease Type
        13.6.2    Retinal Vein Occlusion Market by Treatment Type
    13.7    United Kingdom Retinal Vein Occlusion Market Overview
        13.7.1    Retinal Vein Occlusion Market by Disease Type
        13.7.2    Retinal Vein Occlusion Market by Treatment Type
14    Japan Retinal Vein Occlusion Market
    14.1    Retinal Vein Occlusion Market Historical Value (2017-2023) 
    14.2    Retinal Vein Occlusion Market Forecast Value (2024-2032)
    14.3    Retinal Vein Occlusion Market by Disease Type
    14.4    Retinal Vein Occlusion Market by Treatment Type
15    Patent Analysis
    15.1    Analysis by Type of Patent
    15.2    Analysis by Publication year
    15.3    Analysis by Issuing Authority
    15.4    Analysis by Patent Age
    15.5    Analysis by CPC Analysis
    15.6    Analysis by Patent Valuation 
    15.7    Analysis by Key Players
16    Grants Analysis
    16.1    Analysis by year
    16.2    Analysis by Amount Awarded
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Grant Application
    16.5    Analysis by Funding Institute
    16.6    Analysis by NIH Departments
    16.7    Analysis by Recipient Organization 
17    Clinical Trials Analysis
    17.1     Analysis by Trial Registration Year
    17.2    Analysis by Trial Status
    17.3    Analysis by Trial Phase
    17.4    Analysis by Therapeutic Area
    17.5    Analysis by Geography
18    Funding Analysis
    18.1    Analysis by Funding Instances
    18.2    Analysis by Type of Funding
    18.3    Analysis by Funding Amount
    18.4    Analysis by Leading Players
    18.5    Analysis by Leading Investors
    18.6    Analysis by Geography
19    Partnership and Collaborations Analysis
    19.1    Analysis by Partnership Instances
    19.2    Analysis by Type of Partnership
    19.3    Analysis by Leading Players
    19.4    Analysis by Geography
20    Supplier Landscape
    20.1    Allergan
        20.1.1    Financial Analysis
        20.1.2    Product Portfolio
        20.1.3    Demographic Reach and Achievements
        20.1.4    Mergers and Acquisition
        20.1.5    Certifications
    20.2    Bayer AG
        20.2.1    Financial Analysis
        20.2.2    Product Portfolio
        20.2.3    Demographic Reach and Achievements
        20.2.4    Mergers and Acquisition
        20.2.5    Certifications
    20.3    IRIDEX Corporation
        20.3.1    Financial Analysis
        20.3.2    Product Portfolio
        20.3.3    Demographic Reach and Achievements
        20.3.4    Mergers and Acquisition
        20.3.5    Certifications
    20.4    Lumenis
        20.4.1    Financial Analysis
        20.4.2    Product Portfolio
        20.4.3    Demographic Reach and Achievements
        20.4.4    Mergers and Acquisition
        20.4.5    Certifications
    20.5    Novartis AG
        20.5.1    Financial Analysis
        20.5.2    Product Portfolio
        20.5.3    Demographic Reach and Achievements
        20.5.4    Mergers and Acquisition
        20.5.5    Certifications
    20.6    F. Hoffmann-La Roche Ltd
        20.6.1    Financial Analysis
        20.6.2    Product Portfolio
        20.6.3    Demographic Reach and Achievements
        20.6.4    Mergers and Acquisition
        20.6.5    Certifications
    20.7    Regeneron Pharmaceuticals
        20.7.1    Financial Analysis
        20.7.2    Product Portfolio
        20.7.3    Demographic Reach and Achievements
        20.7.4    Mergers and Acquisition
        20.7.5    Certifications
    20.8    Merck & Co.
        20.8.1    Financial Analysis
        20.8.2    Product Portfolio
        20.8.3    Demographic Reach and Achievements
        20.8.4    Mergers and Acquisition
        20.8.5    Certifications
    20.9    Carl Zeiss
        20.9.1    Financial Analysis
        20.9.2    Product Portfolio
        20.9.3    Demographic Reach and Achievements
        20.9.4    Mergers and Acquisition
        20.9.5    Certifications
    20.10    AbbVie Inc.
        20.10.1    Financial Analysis
        20.10.2    Product Portfolio
        20.10.3    Demographic Reach and Achievements
        20.10.4    Mergers and Acquisition
        20.10.5    Certifications
    20.11    CalciMedica Inc.
        20.11.1    Financial Analysis
        20.11.2    Product Portfolio
        20.11.3    Demographic Reach and Achievements
        20.11.4    Mergers and Acquisition
        20.11.5    Certifications
    20.12    Outlook Therapeutics, Inc.
        20.12.1    Financial Analysis
        20.12.2    Product Portfolio
        20.12.3    Demographic Reach and Achievements
        20.12.4    Mergers and Acquisition
        20.12.5    Certifications
    20.13    Kodiak Sciences Inc.
        20.13.1    Financial Analysis
        20.13.2    Product Portfolio
        20.13.3    Demographic Reach and Achievements
        20.13.4    Mergers and Acquisition
        20.13.5    Certifications
    20.14    Aerie Pharmaceuticals Inc.
        20.14.1    Financial Analysis
        20.14.2    Product Portfolio
        20.14.3    Demographic Reach and Achievements
        20.14.4    Mergers and Acquisition
        20.14.5    Certifications
21    Retinal Vein Occlusion Market - Distribution Model (Additional Insight)
    21.1    Overview 
    21.2    Potential Distributors 
    21.3    Key Parameters for Distribution Partner Assessment 
22    Key Opinion Leaders (KOL) Insights (Additional Insight)
23    Company Competitiveness Analysis (Additional Insight)

    23.1    Very Small Companies
    23.2    Small Companies
    23.3    Mid-Sized Companies
    23.4    Large Companies
    23.5    Very Large Companies
24    Payment Methods (Additional Insight)
    24.1    Government Funded
    24.2    Private Insurance
    24.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 12.4 billion in 2023, driven by the increasing incidence of geriatric population.

The market is anticipated to grow at a CAGR of 13.03% during the forecast period of 2024-2032, likely to reach a market value of USD 37.2 billion by 2032.

The market demand is driven by the rising prevalence of atherosclerosis, which has become common due to the unhealthy lifestyle, obesity, and dietary habits in the modern-day scenario.

The current market trend surrounds the increasing drug approvals for disease management. In October 2023, FDA approved Genentech’s Vabysmo (faricimab-svoa) for the treatment of retinal vein occlusion, based on the positive results from two phase III studies.

Based on treatment types, the market is divided into antivascular endothelial growth factor, corticosteroid drugs, laser retinal photocoagulation and others.

Branch retinal artery occlusion and central retinal vein occlusion are types of retinal occlusions in the market.

Optical coherence tomography (OCT), fundoscopic examination, and fluorescein angiography, among others are the common diagnosis methods in the market.

Based on condition, the market is divided into non-ischemic and ischemic.

Major end users include hospitals, clinics, ambulatory surgical centers, and homecare settings.

The major regions of the market include the United States, Japan, and EU-4, which is further segmented into Germany, France, Italy, Spain, and the United Kingdom.

Key players involved in the market are Allergan, Bayer AG, IRIDEX Corporation, Lumenis, Novartis AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Merck & Co., Carl Zeiss, AbbVie Inc., CalciMedica Inc., Outlook Therapeutics, Inc., Kodiak Sciences Inc., and Aerie Pharmaceuticals Inc.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER